Professor Bloom was assured by the DHSS that prompting "the appropriate manufacturers" to apply for abridged product licences to ensure the supply of heat-treated product was a "high priority item".
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation
Key Person(s)
Professor Arthur L Bloom